TY - JOUR T1 - Children develop strong and sustained cross-reactive immune responses against spike protein following SARS-CoV-2 infection JF - medRxiv DO - 10.1101/2021.04.12.21255275 SP - 2021.04.12.21255275 AU - Alexander C. Dowell AU - Megan S. Butler AU - Elizabeth Jinks AU - Gokhan Tut AU - Tara Lancaster AU - Panagiota Sylla AU - Jusnara Begum AU - Hayden Pearce AU - Graham S. Taylor AU - Eleni Syrimi AU - Eliska Spalkova AU - Sandra Davies AU - Frances Baawuah AU - Joanne Beckmann AU - Ifeanyichukwu Okike AU - Shazaad Ahmad AU - Joanna Garstang AU - Andrew J Brent AU - Bernadette Brent AU - Georgina Ireland AU - Felicity Aiano AU - Zahin Amin-Chowdhury AU - Samuel Jones AU - Ray Borrow AU - Ezra Linley AU - John Poh AU - Vanessa Saliba AU - Gayatri Amirthalingam AU - Kevin E Brown AU - Mary E Ramsay AU - Jianmin Zuo AU - Paul Moss AU - Shamez Ladhani Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/19/2021.04.12.21255275.abstract N2 - SARS-CoV-2 infection is generally mild or asymptomatic in children but the biological basis for this is unclear. We studied the profile of antibody and cellular immunity in children aged 3-11 years in comparison with adults. Antibody profiles in children were strong with high titres against spike protein and receptor binding domain (RBD). SARS-CoV-2 seroconversion in children strongly boosted antibody responses against seasonal beta-coronaviruses, partly through cross-recognition of the S2 domain, indicating a broad humoral response that was not seen in adults. T cell responses against spike were also >2-fold higher in children compared to adults and displayed a strong Th1 cytokine profile. SARS-CoV-2 spike-reactive cellular responses were present in more than half the seronegative children, indicating pre-existing cross-reactive responses or sensitization against SARS-CoV-2. Importantly, all children retained high antibody titres and cellular responses for more than 6 months after infection whilst relative antibody waning was seen in adults. Children thus distinctly generate robust, cross-reactive and sustained immune responses after SARS-CoV-2 infection with focussed specificity against spike protein. These observations demonstrate several novel features of SARS-CoV-2-specific immune responses in children and may provide insights into relative clinical protection in this group. Such information on the profile of natural infection will help to guide the introduction of vaccination regimens into the paediatric population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was part funded by the MRC and the UK Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PHE Research Ethics Governance Group (reference NR0209; May 16, 2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available following reasonable requests. ER -